NCT06074822 Research Biobank From Neuromuscular Biopsy Residues (in the Context of Care)
| NCT ID | NCT06074822 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Neuromuscular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-06-26 |
| Primary Completion | 2053-06-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-06-26 with a primary completion date of 2053-06-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neuromuscular diseases are rare diseases for which significant progress has been made in the context of diagnosis thanks to advances in molecular techniques, but the intimate mechanisms of lesion formation remain poorly understood. Advances in cellular and molecular biology, the development of a few animal models, such as transgenic mice, which make it possible to mimic human pathology have made it possible to better understand the physiopathology of these diseases. However, they still do so very imperfectly and incompletely, making it even more necessary than ever to study diseased human muscle tissue to find new avenues of research or to confirm results obtained by experimentation. The purpose of this collection of tissue samples for neuro-muscular purposes is to collect such samples under the best conditions in order to promote basic and translational research on muscle diseases. This is why the CHU de Bordeaux wishes to keep the remainders of samples taken as part of the treatment to constitute a collection of biological samples and associated data kept according to quality standards and in compliance with the regulations in force.
Eligibility Criteria
Inclusion criteria * Patients treated at Bordeaux University Hospital (neurology services, neuropediatrics), rheumatology, medical genetics for suspected neuromuscular disease. * Men and women are affected, adults and minors. Exclusion criteria \- no exclusion criteria
Contact & Investigator
Marie Laure NEGRIER, Pr
PRINCIPAL INVESTIGATOR
Université Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT06074822 clinical trial?
This trial is open to participants of all sexes, studying Neuromuscular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06074822 currently recruiting?
Yes, NCT06074822 is actively recruiting participants. Contact the research team at marie-laure.martin-negrier@chu-bordeaux.fr for enrollment information.
Where is the NCT06074822 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT06074822 clinical trial?
NCT06074822 is sponsored by University Hospital, Bordeaux. The principal investigator is Marie Laure NEGRIER, Pr at Université Hospital, Bordeaux. The trial plans to enroll 500 participants.